HRES601-119

That it is the sense of the House of Representatives that— the biomedical research of the United States and development capacity is a national asset that must be protected, improved, and expanded; Federal Government efforts through the National Institutes of Health ensure a robust biomedical research apparatus and support the global role of the United States as a leader of biomedical advancement and innovation; the biomedical research workforce of the United States, including the public servants at the National Institutes of Health and other Federal agencies, should be treated with respect, and the jobs associated with biomedical research should offer good pay and benefits; protecting public health must be a whole-of-government collaboration beginning with the research necessary to advance public health; Federal Government support is integral to— training new scientists in varied public health and research disciplines; encouraging and facilitating premier scientists to stay in the United States for their careers; ensuring a robust field of scientists in the United States who are committed to the advancement of science, public health, and biomedicine; and stability of biomedical research funding so that United States-based researchers are focused on science and advancement rather than administrative burdens or political interference; scientific decision making in the Federal Government should be driven by the best available evidence, effectuated by peer-reviewed scientists, and insulated from political interference; over the next decade, the Federal Government should double its investment in biomedical research and properly applying the findings of biomedical research to medical practice; Federal biomedical research investments should— support basic research that improves our understanding of the human body in all its diversity, and how external factors such as lifestyle factors, social factors, and environmental factors affect its function; support research that seeks to clarify the root causes of diseases; support translational science that accelerates access of Americans to novel treatments; support potentially transformative high-risk, high-reward research; support and enable collaborative, broad-based resources that may be used across different researchers and institutions; support and enable research collaboration across individual researchers and institutions and facilitate knowledge sharing; serve a dual mandate of increasing understanding of a particular scientific question and increasing the capacity of funded researchers and institutions to perform future research of value; support transparency, accountability, and replicability in innovative biomedical research; support novel processes, products, and other innovations that have the potential to prevent, mitigate, or cure disease, particularly those which may reduce overall health care expenditures; and support the integration of evidence generated by biomedical research into clinical practice, including by expanding partnerships with Federal health agencies, health professionals, patients, health systems, payors, industry, and community-based organizations; and it should be the policy of the Federal Government to invest in research with the potential to improve the quality of life for all Americans and innovations in medicine, including— reversing the recent decline in United States life expectancy; developing technologies to ensure the ability to prevent and respond to microbial threats to humans and animals; identifying the underlying causes of neurogenerative diseases and developing tools to reduce the burden of such diseases; reducing the death rate from cancer and improving the quality of life of those diagnosed with cancer; reducing the burden of Alzheimer’s disease and related dementias, including by developing evidence-based tools to effectively prevent Alzheimer’s disease; reducing the number of people who die waiting for transplantable organs to zero; avoiding preventable diabetes diagnoses; reducing deaths from cardiovascular disease, including stroke; developing versatile therapeutic platforms that can be repurposed for various applications, including treatments for ultrarare genetic diseases; developing effective interventions to prevent and treat chronic symptoms of viral and bacterial infections, including COVID–19, Lyme disease, and Epstein-Barr virus; developing effective preventive vaccines and therapeutics for diseases that have historically affected underserved populations worldwide and attracted lower levels of investment, such as chikungunya, dengue, and malaria; and improving representation in clinical trials to ensure broad applicability of scientific findings and improve the health of underserved populations.